Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies

被引:83
作者
Goldberg, Terry E. [1 ]
Keefe, Richard S. E. [2 ]
Goldman, Robert S. [3 ]
Robinson, Delbert G. [1 ]
Harvey, Philip D. [4 ]
机构
[1] Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY 11004 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Pfizer, New York, NY USA
[4] Emory Univ, Atlanta, GA 30322 USA
基金
英国医学研究理事会;
关键词
cognition; schizophrenia/antipsychotics; clinical pharmacology/trials; learning and memory; practice effects; NEUROPSYCHOLOGICAL DEFICITS; 1ST-EPISODE SCHIZOPHRENIA; ANTIPSYCHOTIC MEDICATIONS; NEUROCOGNITIVE FUNCTION; COGNITIVE FUNCTION; ALTERNATE FORMS; METAANALYSIS; HALOPERIDOL; RELIABILITY; PERFORMANCE;
D O I
10.1038/npp.2009.211
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first-and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive 'positive' findings. Thus, this review suggests that many previous findings can be reinterpreted in this light. Critically, we also make several suggestions about test construction, study design, and statistical analyses that the field might use to overcome this potential confound. Our suggestions may also have implications for drug discovery and regulatory approval of cognitive-enhancing adjunctive agents, in terms of study design and/or test psychometric characteristics, including the development of tests that are relatively insensitive to practice-related changes. Such advances might be important for improving the methodology involved in the assessment of cognitive change in treatment studies. Neuropsychopharmacology (2010) 35, 1053-1062; doi: 10.1038/npp.2009.211;published online 20 January 2010
引用
收藏
页码:1053 / 1062
页数:10
相关论文
共 50 条
[1]   Changes in Neurocognitive Function in Patients With Schizophrenia After Starting or Switching to Amisulpride in Comparison With the Normal Controls [J].
Ahn, Yong Min ;
Lee, Kyu Young ;
Kim, Chul-Eung ;
Kim, Jae-Jin ;
Kang, Dae-Yeob ;
Jun, Tae-Youn ;
Choi, Jin Sook ;
Chung, In-Won ;
Kim, Se Hyun ;
Hwang, Samuel S. -H. ;
Kim, Yong Sik .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (02) :117-123
[2]   Neurocognitive functioning in patients with first-episode schizophrenia -: Results of a prospective 5-year follow-up study [J].
Albus, Margot ;
Hubmann, Werner ;
Mohr, Fritz ;
Hecht, Susanne ;
Hinterberger-Weber, Petra ;
Seitz, Nichi-Niels ;
Kuechenhoff, Helmut .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2006, 256 (07) :442-451
[3]  
[Anonymous], 1999, MODELS WORKING MEMOR, DOI [10.1017/CBO9781139174909.006, DOI 10.1017/CBO9781139174909.006]
[4]   Practice effects on commonly used measures of executive function across twelve months [J].
Basso, MR ;
Bornstein, RA ;
Lang, JM .
CLINICAL NEUROPSYCHOLOGIST, 1999, 13 (03) :283-292
[5]   Practice effects and the use of alternate forms in serial neuropsychological testing [J].
Beglinger, LJ ;
Gaydos, B ;
Tangphao-Daniels, O ;
Duff, K ;
Kareken, DA ;
Crawford, J ;
Fastenau, PS ;
Siemers, ER .
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2005, 20 (04) :517-529
[6]  
Boulay Luc J, 2007, Cogn Neuropsychiatry, V12, P322, DOI 10.1080/13546800601069534
[7]   Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms [J].
Bowie, CR ;
Reichenberg, A ;
Patterson, TL ;
Heaton, RK ;
Harvey, PD .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (03) :418-425
[8]   Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis: A Randomized, Controlled 1-Year Follow-Up Comparison [J].
Crespo-Facorro, Benedicto ;
Rodriguez-Sanchez, Jose M. ;
Perez-Iglesias, Rocio ;
Mata, Ignacio ;
Ayesa, Rosa ;
Ramirez-Bonilla, MariLuz ;
Martinez-Garcia, Obdulia ;
Vasquez-Barquero, Jose L. .
JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (05) :717-729
[9]   Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST) [J].
Davidson, Michael ;
Galderisi, Silvana ;
Weiser, Mark ;
Werbeloff, Nomi ;
Fleischhacker, Wolfgang W. ;
Keefe, Richard S. ;
Boter, Han ;
Keet, Ireneus P. M. ;
Prelipceanu, Dan ;
Rybakowski, Janusz K. ;
Libiger, Jan ;
Hummer, Martina ;
Dollfus, Sonia ;
Lopez-Ibor, Juan J. ;
Hranov, Luchezar G. ;
Gaebel, Wolfgang ;
Peuskens, Joseph ;
Lindefors, Nils ;
Riecher-Roessler, Anita ;
Kahn, Rene S. .
AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (06) :675-682
[10]   The placebo effect in neurological disorders [J].
de la Fuente-Fernández, R ;
Schulzer, M ;
Stoessel, AJ .
LANCET NEUROLOGY, 2002, 1 (02) :85-91